PCSK9 and familial hyperaldosteronism: Furthermore, lymphocytes from patients with homozygous FH can effectively take up Lp(a) particles, and PCSK9 inhibitors can lower circulating Lp(a) in homozygous FH patients (56), indicating a LDLR-independent pathway.